Targeting MAPK Signaling Pathway with Cobimetinib (GDC-0973) Enhances Anti-Leukemia Efficacy of Venetoclax (ABT-199/GDC-0199) in Acute Myeloid Leukemia Models

被引：2

作者：

Han, Lina ^{[1
]}

Zhang, Qi ^{[1
]}

Shi, Ce ^{[2
]}

Cavazos, Antonio ^{[1
]}

Ruvolo, Vivian ^{[1
]}

Leverson, Joel ^{[3
]}

Monique, Dail ^{[4
]}

Phillips, Darren C. ^{[3
]}

Chen, Jun ^{[3
]}

Jin, Sha S. ^{[3
]}

Jacamo, Rodrigo Omar ^{[1
]}

Daver, Naval ^{[1
]}

Jabbour, Elias J. ^{[1
]}

Kantarjian, Hagop M. ^{[1
]}

Andreeff, Michael ^{[1
]}

Sampath, Deepak ^{[4
]}

Konopleva, Marina ^{[1
]}

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA

[2] Harbin Med Univ, Affiliated Hosp 1, Dept Leukemia, Harbin, Peoples R China

[3] AbbVie Inc, N Chicago, IL USA

[4] Genentech Inc, San Francisco, CA USA

来源：

BLOOD | 2016年 / 128卷 / 22期

关键词：

D O I：

10.1182/blood.V128.22.97.97

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 45 条

[41] Results of the Safety Run-in Phase of CLL14 (BO25323): A Prospective, Open-Label, Multicenter Randomized Phase Ill Trial to Compare the Efficacy and Safety of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) with Obinutuzumab and Chlorambucil in Patients with Previously Untreated CLL and Coexisting Medical Conditions
Fischer, Kirsten
Fink, Anna-Maria
Bishop, Helen
Dixon, Mark
Bahlo, Jasmin
Chol, Michael Y.
Weinkove, Robert
Robinson, Sue
Dreyling, Martin
Seiler, Till
Opat, Stephen
Owen, Carolyn
Lopez, Javier, Sr.
Kutsch, Nadine
Tausch, Eugen
Ritgen, Matthias
Humerickhouse, Rod A.
Humphrey, Kathryn
Wenger, Michael K.
Goede, Valentin
Eichhorst, Barbara
Wendtner, Clemens-Martin
Stilgenbauer, Stephan
Kipps, Thomas J.
Hallek, Michael
BLOOD, 2015, 126 (23)
[42] Combination of the glycoengineered Type II CD20 antibody obinutuzumab (GA101), and the novel Bcl-2 selective inhibitor, ABT-199 (GDC-0199), results in superior in vitro and in vivo anti-tumor activity in models of B-cell malignancies.
Sampath, Deepak
Herter, Sylvia
Ingalla, Ellen
Herting, Frank
Bacac, Marina
Nannini, Michelle
Fairbrother, Wayne J.
Klein, Christian
MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
[43] BCL-2 Antagonist ABT-199 Combined with Complex I Inhibitor IACS-010759 Blocks Mitochondrial Respiration and Facilitates Anti-Leukemia Efficacy in Pre-Clinical AML Models
Zhang, Qi
Han, Lina
Cai, Tianyu
Kuruvilla, Vinitha Mary
Cavazos, Antonio
Ma, Helen
Battula, Venkata Lokesh
Baran, Natalia
Harutyunyan, Karine
Andreeff, Michael
Tabe, Yoko
Marszalek, Joseph R.
Konopleva, Marina
BLOOD, 2017, 130
[44] Inhibition of XPO1 By KPT-330 (Selinexor) Enhances Cell Death Induced By the Bcl-2 Selective Inhibitor ABT-199 (Venetoclax) through Downregulation of Mcl-1 in Acute Myeloid Leukemia
Luedtke, Daniel A.
Su, Yongwei
Edwards, Holly
Lin, Hai
Taub, Jeffrey W.
Ge, Yubin
BLOOD, 2017, 130
[45] Targeting E-selectin/CXCR4 with GMI-1359 effectively mobilizes bone marrow leukemia cells and enhances FLT3 inhibitor-induced anti-leukemia efficacy in a murine acute myeloid leukemia model
Zhang, Weiguo
Mu, Hong
Zhang, Qi
Patel, Nalini B.
Fogler, William E.
Magnani, John L.
Andreeff, Michael
CANCER RESEARCH, 2016, 76

← 1 2 3 4 5 →